Molecular Identification of Acinetobacter baumanii and Acinetobacter genomic species 13TU Using PCR

Main Article Content

Salah Tofik Jalal Balaky
Haval Abdulkhalik
Bashdar Mahmud Hussen
Hozan Hassan
Ahang Hasan Mawlood


Acinetobacter baumannii; genomic 13TU, gyrB gene, PCR, Resistance.


Acinetobacter baumannii is well known to be multi-drug resistant and associated with many infectins. Manual and automated identification systems, can not differentiate between both species A. baumannii and Acinetobacter genomic species 13TU. The reason is the differences in nucleotide sequences in gyrB of both species, therefore, specific genotypic test required for differentiating them. The aim of this study is to differentiate between two species of Acinetobacter based on gyrB gene nucleotide sequence differences and their antibiotic resistance profile in Erbil city. Six hundred thirty two clinical specimens were collected during the period of March to August 2016. Colony, cultural morphology and VITEK2 system were used, in which 105 of them were A. baumannii. PCR was then used to differentiate between A. baumannii and Acinetobacter genomic species 13TU. Out of 632 clinical specimens, 105 were phenotypically identified as Acinetobacter baumannii using VITEK2 system. PCR results showed that Acinetobacter genomic species 13TU gave an amplicon of 294 bp as one band, but A. baumannii gave a second amplicon of 490 bp. The PCR method correctly identified 43 A. baumannii and 62 Acinetobacter genomic 13TU. Carbapenem resistance was observed 60% (n=40), infection among male 69.53% (n=73) was higher than female. PCR detection of Acinetobacter species showed high sensitivity and accuracy as compared to other phynotypic methods. To the best of our knowledge this is the first study performed to differentiate two important species of Acinetobacter in Kurdistan region.

Abstract 70 | PDF Downloads 58


Abbo, A., Navon-Venezia, S., Hammer-Muntz, O., Krichali, T., Siegman-Igra, Y. and Carmeli, Y., 2005. Multidrug-resistant Acinetobacter baumannii. Emerging infectious diseases, 11(1), p.22.
Briñas, L., Zarazaga, M., Sáenz, Y., Ruiz-Larrea, F. and Torres, C., 2002. β-Lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals. Antimicrobial agents and chemotherapy, 46(10), pp.3156-3163.
Chan, J.Z., Halachev, M.R., Loman, N.J., Constantinidou, C. and Pallen, M.J., 2012. Defining bacterial species in the genomic era: insights from the genus Acinetobacter. BMC microbiology, 12(1), p.302.
Chang, H.C., Wei, Y.F., Dijkshoorn, L., Vaneechoutte, M., Tang, C.T. and Chang, T.C., 2005. Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. Journal of clinical microbiology, 43(4), pp.1632-1639.
Dijkshoorn, L., Nemec, A. and Seifert, H., 2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nature reviews microbiology, 5(12), p.939.
Dijkshoorn, L., van Harsselaar, B., Tjernberg, I., Bouvet, P.J. and Vaneechoutte, M., 1998. Evaluation of amplified ribosomal DNA restriction analysis for identification of Acinetobacter genomic species. Systematic and applied microbiology, 21(1), pp.33-39.
Higgins, P.G., Dammhayn, C., Hackel, M. and Seifert, H., 2009. Global spread of carbapenem-resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 65(2), pp.233-238.
Higgins, P.G., Lehmann, M., Wisplinghoff, H. and Seifert, H., 2010. gyrB multiplex PCR to differentiate between Acinetobacter calcoaceticus and Acinetobacter genomic species 3. Journal of clinical microbiology, 48(12), pp.4592-4594.
Higgins, P.G., Wisplinghoff, H., Krut, O. and Seifert, H., 2007. A PCR‐based method to differentiate between Acinetobacter baumannii and Acinetobacter genomic species 13TU. Clinical microbiology and infection, 13(12), pp.1199-1201.
Horrevorts, A., Bergman, K., Kollee, L., Breuker, I., Tjernberg, I. and Dijkshoorn, L., 1995. Clinical and epidemiological investigations of Acinetobacter genomospecies 3 in a neonatal intensive care unit. Journal of clinical microbiology, 33(6), pp.1567-1572.
Karlowsky, J.A., Draghi, D.C., Jones, M.E., Thornsberry, C., Friedland, I.R. and Sahm, D.F., 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrobial agents and chemotherapy, 47(5), pp.1681-1688.
Lee, J.H., Choi, C.H., Kang, H.Y., Lee, J.Y., Kim, J., Lee, Y.C., Seol, S.Y., Cho, D.T., Kim, K.W., Song, D.Y. and Lee, J.C., 2007. Differences in phenotypic and genotypic traits against antimicrobial agents between Acinetobacter baumannii and Acinetobacter genomic species 13TU. Journal of antimicrobial chemotherapy, 59(4), pp.633-639.
Maleki, A., Vandyousefi, J., Mirzaie, Z., Ghafourian, S., Kazemian, H. and Sadeghifard, N., 2017. Molecular Analysis of the Isolates of Acinetobacter baumannii isolated from Tehran Hospitals Using ERIC-PCR Method. Modern Medical Laboratory Journal, 1(1), pp.12-16.
Nemec, A., Krizova, L., Maixnerova, M., van der Reijden, T.J., Deschaght, P., Passet, V., Vaneechoutte, M., Brisse, S. and Dijkshoorn, L., 2011. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus–Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov.(formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov.(formerly Acinetobacter genomic species 13TU). Research in microbiology, 162(4), pp.393-404.
Paterson, D.L., Hujer, K.M., Hujer, A.M., Yeiser, B., Bonomo, M.D., Rice, L.B. and Bonomo, R.A., 2003. Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV-and CTX-M-type β-lactamases. Antimicrobial agents and chemotherapy, 47(11), pp.3554-3560.
Pourabbas B., Roya Firouzi and Gholamreza Pouladfar, 2016. Characterization of carbapenem-resistant Acinetobacter calcoaceticus–baumannii complex isolates from nosocomial bloodstream infections in southern Iran. Journal of Medical Microbiology, 65, 235–239.
Turkoglu, M., Mirza, E., Tunçcan, Ö.G., Erdem, G.U., Dizbay, M., Yağcı, M., Aygencel, G. and Sucak, G.T., 2011. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. Journal of critical care, 26(5), pp.460-467.
Uwingabiye, J., Frikh, M., Lemnouer, A., Bssaibis, F., Belefquih, B., Maleb, A., Dahraoui, S., Belyamani, L., Bait, A., Haimeur, C. and Louzi, L., 2016. Acinetobacter infections prevalence and frequency of the antibiotics resistance: comparative study of intensive care units versus other hospital units. Pan African Medical Journal, 23(1).
Van Looveren, M., Goossens, H. and ARPAC Steering Group, 2004. Antimicrobial resistance of Acinetobacter spp. in Europe. Clinical microbiology and infection, 10(8), pp.684-704.
Visca, P., Seifert, H. and Towner, K.J., 2011. Acinetobacter infection–an emerging threat to human health. IUBMB life, 63(12), pp.1048-1054.
Zarrilli, R., Giannouli, M., Di Popolo, A., Tomasone, F. and Chu, Y.W., 2009. Identification of Acinetobacter genomic species 13TU by sequence analysis of the 16S-23S rRNA gene spacer region. Journal of clinical microbiology, 47(4), pp.1281-1282.
Zarrilli, R., Giannouli, M., Tomasone, F., Triassi, M. and Tsakris, A., 2009. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. The Journal of Infection in Developing Countries, 3(05), pp.335-341.